Basket | Login | Register


P10. Alzheimer Cooperative Valuation in Europe (ALCOVE)

Detailed programme, abstracts and presentations

P10. Alzheimer Cooperative Valuation in Europe (ALCOVE)

Leperre Desplanques Armelle, Brooker Dawn, Gove Dianne, Krolak-Salmon Pierre

ALCOVE was born out of a need to share knowledge and experiences about Alzheimer’s disease and related disorders in health policy between European Member States. Nineteen countries were committed to this 2-year Joint Action, and were represented by thirty organisations which were appointed by their respective governments.  ALCOVE acted in order to position and synergise its public health missions with respect to other Alzheimer initiatives and research projects in Europe. In particular, a formal, close, and fruitful cooperation was established with Alzheimer Europe.

The general objective of this ALCOVE Joint Action was to establish an independent and scientific European network to inform and advise decision-makers, health care professionals, family carers, individuals living with dementia, and other European citizens through convergent operational recommendations from a health policy perspective. The 5 specific objectives were to improve (1) epidemiological data on dementia, notably its prevalence, (2) the diagnosis, in terms of time and quality, (3) the support systems for BPSD, main cause of family burden and institutionalisation, (4) the rights and dignity of people living with dementia through a better use of advance directives of will and of competence assessment, (5) the use of antipsychotics with their reduction for a better quality of life of people. What do we know in scientific terms? What is the situation in Europe? Each of the five objectives has been analysed while using these two questions to contextualise ALCOVE’s work. In answering these questions, ALCOVE’s aim is to make concrete recommendations which propose avenues for improvement.

As a result of this work, ALCOVE is able to present operational proposals for several key aspects for improving, from a public health standpoint, care pathways and the quality of life for persons living with dementia as well as their carers:  improve knowledge about dementia prevalence so as to be able to better anticipate needs; propose a diagnosis at a time when it brings most benefit, such a diagnosis should be accessible and accompanied by post diagnostic interventions  for persons living with dementia and their families; design a public health strategy for the disturbing behaviours related to BPSD, and in doing so reducing burn-out among carers and allowing the person to stay in his or her home for the longest period possible; improve the respect of the rights and dignity of people living with dementia by encouraging good practices in advance directive and competency assessment use; limit the inappropriate use of antipsychotics which is an ethical and safety issue shared by all European countries.

The ALCOVE collaborative approach which promotes benchmarking and sharing between European Member States is an opportunity to reform and to innovate much more quickly, i.e. refer to these recommendations in national guidelines or account for them in their specific health project plans. ALCOVE’s proposals aim to improve care and quality of life for persons living with dementia and their family carers in Europe.ALCOVE Joint Action: an overview 



Last Updated: Thursday 31 October 2013


  • Acknowledgements

    The 23rd Alzheimer Europe Conference in St. Julian's, Malta received funding from the European Union, in the framework of the Health Programme. Alzheimer Europe and the Malta Dementia Society gratefully acknowledge the additional support provided by foundations and companies.
  • European Union